atezolizumab
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: Programmed cell death 1 ligand 1.
- Target
- Programmed cell death 1 ligand 1
- Mechanism
- Programmed cell death 1 ligand 1 inhibitor
biotech · Recurrent Plasma Cell Myeloma · Anal Cancer Metastatic · ONCY
Oncolytics Biotech
ONCOLYTICS BIOTECH INC
Oncolytics Biotech drug portfolio — 14 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
4350 Executive Dr, 325, San Diego, California 92121, US HQ
1998 Founded
46 Employees
Public company Type
ONCY · NYSE Ticker
Company details
- Status
- Public
- HQ
- 4350 Executive Dr, 325, San Diego, California 92121, US
- Founded
- 1998
- Employees
- 46
- Programs
- 23
- Drugs
- 14
- Patents
- 66
Oncolytics Biotech pipeline
Portfolio lens on 14 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
Oncolytics Biotech drug portfolio — 14 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
bevacizumab
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: Vascular endothelial growth factor A, long form.
- Target
- Vascular endothelial growth factor A, long form
- Mechanism
- Vascular endothelial growth factor A inhibitor
-
bortezomib
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: 26S proteasome.
- Target
- 26S proteasome
- Mechanism
- 26S proteosome inhibitor
-
carfilzomib
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: 26S proteasome.
- Target
- 26S proteasome
- Mechanism
- 26S proteosome inhibitor
-
docetaxel
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: Tubulin.
- Target
- Tubulin
- Mechanism
- Tubulin inhibitor
-
Development asset linked to Oncolytics Biotech in public FDA and regional records.
-
lenalidomide
Antineoplastic and immunomodulating agents (L04)US regulatory status: approved. Molecular target: CRL4(CRBN) E3 ubiquitin ligase.
- Target
- CRL4(CRBN) E3 ubiquitin ligase
- Mechanism
- CRL4(CRBN) E3 ubiquitin ligase inhibitor
-
Development asset linked to Oncolytics Biotech in public FDA and regional records.
-
paclitaxel
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: Tubulin.
- Target
- Tubulin
- Mechanism
- Tubulin inhibitor
-
US regulatory status: approved. Molecular target: Dihydrofolate reductase.
- Target
- Dihydrofolate reductase
- Mechanism
- Thymidylate synthase inhibitor
-
pomalidomide
Antineoplastic and immunomodulating agents (L04)US regulatory status: approved. Molecular target: CRL4(CRBN) E3 ubiquitin ligase.
- Target
- CRL4(CRBN) E3 ubiquitin ligase
- Mechanism
- CRL4(CRBN) E3 ubiquitin ligase inhibitor
-
US regulatory status: approved. Molecular target: Glucocorticoid receptor.
- Target
- Glucocorticoid receptor
- Mechanism
- Glucocorticoid receptor agonist
-
Development asset linked to Oncolytics Biotech in public FDA and regional records.
-
Development asset linked to Oncolytics Biotech in public FDA and regional records.